G. White

Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432.

Darren L. Poole, I. Wall, P. Bamborough, 2022, Journal of medicinal chemistry.

Oxygenated Cyclopentenones via the Pauson–Khand Reaction of Silyl Enol Ether Substrates

W. Kerr, A. Kennedy, L. C. Paterson, 2022, Organic letters.

Synthesis and evaluation of novel alpha-amino cyclic boronates as inhibitors of HCV NS3 protease.

Z. Ni, P. Rowland, S. Baker, 2010, Bioorganic & medicinal chemistry letters.

Evaluation of a crystallographic surrogate for kallikrein 5 in the discovery of novel inhibitors for Netherton syndrome.

A. Hovnanian, J. Liddle, Kathrine J. Smith, 2019, Acta crystallographica. Section F, Structural biology communications.

4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.

Christopher Browning, Helen Connor, David M. Wilson, 2007, Journal of medicinal chemistry.

Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase.

Michelle C. Schaeffer, Carol A. Capriotti, Paul E. Lamoureux, 2019, Journal of medicinal chemistry.

Acetylation of the Catalytic Lysine Inhibits Kinase Activity in PI3Kδ.

Dan Thomas, Sebastien Campos, F. Zappacosta, 2021, ACS chemical biology.

Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome.

A. Hovnanian, J. Liddle, Kathrine J. Smith, 2019, Bioorganic & medicinal chemistry letters.

Acetylation of the Catalytic Lysine Inhibits Kinase Activity in PI3Kδ.

Dan Thomas, Sebastien Campos, F. Zappacosta, 2020, ACS chemical biology.